AnaptysBio (NASDAQ: ANAB) is one of 297 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare AnaptysBio to similar companies based on the strength of its risk, analyst recommendations, dividends, earnings, valuation, institutional ownership and profitability.
Institutional & Insider Ownership
52.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 17.5% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
AnaptysBio has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500. Comparatively, AnaptysBio’s competitors have a beta of 2.29, indicating that their average share price is 129% more volatile than the S&P 500.
This is a breakdown of recent recommendations and price targets for AnaptysBio and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AnaptysBio currently has a consensus price target of $136.63, indicating a potential upside of 16.90%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 38.87%. Given AnaptysBio’s competitors higher possible upside, analysts clearly believe AnaptysBio has less favorable growth aspects than its competitors.
This table compares AnaptysBio and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares AnaptysBio and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|AnaptysBio||$10.00 million||-$4.25 million||-71.70|
|AnaptysBio Competitors||$269.67 million||-$28.62 million||-31.88|
AnaptysBio’s competitors have higher revenue, but lower earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
AnaptysBio competitors beat AnaptysBio on 7 of the 13 factors compared.
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company’s ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.